tiprankstipranks
Trending News
More News >
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
Germany Market
Advertisement

Novo Nordisk (NOVA) Earnings Dates, Call Summary & Reports

Compare
134 Followers

Earnings Data

Report Date
Feb 04, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.81
Last Year’s EPS
0.77
Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 05, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in sales and continued expansion in obesity care, supported by strategic acquisitions. However, significant challenges remain, including market share loss, restructuring efforts, and pricing pressures.
Company Guidance
During the Q3 2025 Novo Nordisk Earnings Conference Call, the company reported impressive financial metrics for the first nine months of 2025, including a 15% sales growth and a 10% operating profit growth. They updated their guidance, narrowing the sales growth range to 8% to 11% and operating profit growth to 4% to 7%, citing lower expectations for their GLP-1 treatments in diabetes and obesity. Novo Nordisk also highlighted strategic initiatives, such as the approval of Rybelsus in the U.S. and EU based on the SOUL trial, and the submission of Mim8 for regulatory approval in rare diseases. The company emphasized their commitment to core areas like diabetes and obesity, expecting significant long-term volume opportunities. They also announced a company-wide transformation to reallocate resources, expecting about DKK 8 billion in annual savings by the end of 2026, with a reduction of approximately 9,000 positions globally.
Strong Sales and Profit Growth
Novo Nordisk achieved a 15% sales growth and a 10% operating profit growth for the first 9 months of 2025.
Expansion in Obesity Care
Obesity care sales increased by 41%, with significant growth in international operations by 83%.
Launch of Wegovy Pill
Novo Nordisk is preparing for the launch of the Wegovy pill in the U.S., with potential launches in selected international markets.
Strategic Acquisitions
Novo Nordisk announced acquisitions of Akero and Omeros' zaltenibart assets to strengthen their pipeline in diabetes and obesity.

Novo Nordisk (DE:NOVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DE:NOVA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 04, 2026
2025 (Q4)
0.81 / -
0.77
Nov 05, 2025
2025 (Q3)
0.66 / 0.60
0.765-21.45% (-0.16)
Aug 06, 2025
2025 (Q2)
0.80 / 0.81
0.57241.19% (+0.24)
May 07, 2025
2025 (Q1)
0.79 / 0.86
0.70722.24% (+0.16)
Feb 05, 2025
2024 (Q4)
0.72 / 0.77
0.62223.74% (+0.15)
Nov 06, 2024
2024 (Q3)
0.76 / 0.77
0.61823.91% (+0.15)
Aug 07, 2024
2024 (Q2)
0.62 / 0.57
0.5543.13% (+0.02)
May 02, 2024
2024 (Q1)
0.65 / 0.71
0.56325.62% (+0.14)
Jan 31, 2024
2023 (Q4)
0.58 / 0.62
0.37565.74% (+0.25)
Nov 02, 2023
2023 (Q3)
0.59 / 0.62
0.36569.29% (+0.25)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:NOVA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 05, 2025
€42.00€41.85-0.36%
Aug 06, 2025
€40.18€38.39-4.44%
May 07, 2025
€57.54€58.53+1.72%
Feb 05, 2025
€78.22€80.18+2.51%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Novo Nordisk (DE:NOVA) report earnings?
Novo Nordisk (DE:NOVA) is schdueled to report earning on Feb 04, 2026, Before Open (Confirmed).
    What is Novo Nordisk (DE:NOVA) earnings time?
    Novo Nordisk (DE:NOVA) earnings time is at Feb 04, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Novo Nordisk stock?
          The P/E ratio of Novo Nordisk is N/A.
            What is DE:NOVA EPS forecast?
            DE:NOVA EPS forecast for the fiscal quarter 2025 (Q4) is 0.81.

              Novo Nordisk (DE:NOVA) Earnings News

              Novo Nordisk Shares Down 44% YTD as Wegovy Sales Jump 67%, But Guidance Stays Lower
              Premium
              Market News
              Novo Nordisk Shares Down 44% YTD as Wegovy Sales Jump 67%, But Guidance Stays Lower
              4M ago
              Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here’s What to Expect
              Premium
              Market News
              Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here’s What to Expect
              4M ago
              NVO Earnings: Novo Nordisk Stock Rises Despite Cutting Fiscal 2025 Outlook
              Premium
              Market News
              NVO Earnings: Novo Nordisk Stock Rises Despite Cutting Fiscal 2025 Outlook
              7M ago
              NVO Earnings: Novo Nordisk Exceeds Q3 Earnings, Narrows Outlook
              Premium
              Market News
              NVO Earnings: Novo Nordisk Exceeds Q3 Earnings, Narrows Outlook
              1y ago
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis